Back to search results

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

Abroad (travel likely)RecruitingPHASE1

Conditions

Hypercholesterolemia · Hypertriglyceridemia · Refractory Hyperlipidemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Clinical Study Center, Clearwater, Florida, United States

  • Clinical Study Center, Miami Lakes, Florida, United States

  • Clinical Study Center, Port Orange, Florida, United States

  • Clinical Study Center, New York, New York, United States

  • Clinical Study Center, Adelaide, Australia

  • Clinical Study Center, Melbourne, Australia

  • Clinical Study Center, Chicoutimi, Canada

  • Clinical Study Center, Montreal, Canada

  • Clinical Study Center, Toronto, Canada

  • Clinical Study Center, Amsterdam, Netherlands

  • Clinical Study Center, Cape Town, South Africa

  • Clinical Study Center, Johannesburg, South Africa

  • Clinical Study Center, Liverpool, United Kingdom

  • Clinical Study Center, London, United Kingdom

  • Clinical Study Center 2, Manchester, United Kingdom

  • Clinical Study Center, Manchester, United Kingdom

Study leads

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

    Study Director

    Eli Lilly and Company

View source on ClinicalTrials.gov(opens in a new tab)